← Back to Search

Monoclonal Antibodies

Participants With AD: Dupilumab for Atopic Dermatitis (DIFFEREN-STAD Trial)

Phase 4
Waitlist Available
Research Sponsored by Sanofi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 17 and 21
Awards & highlights

DIFFEREN-STAD Trial Summary

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

Eligible Conditions
  • Atopic Dermatitis

DIFFEREN-STAD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 17 and 21
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, weeks 17 and 21 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17
Percentage of Participants With Change From Baseline in Nerve Fiber Branching on Lesional Skin at Week 17
Secondary outcome measures
Change From Baseline in Atopic Dermatitis Control Tool (ADCT) Total Score at Weeks 17 and 21
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 17 and 21
Change From Baseline in Eczema and Severity Index (EASI) Total Score at Weeks 17 and 21
+11 more

DIFFEREN-STAD Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Participants With AD: DupilumabExperimental Treatment1 Intervention
Participants with moderate to severe AD received dupilumab 600 milligrams (mg) subcutaneous (SC) injection on Day 1, followed by dupilumab 300 mg SC injection every 2 weeks (Q2W) from Week 3 to Week 15.
Group II: Healthy Participants: ControlActive Control1 Intervention
Healthy participants with site, age, gender, race, location of targeted lesional and non-lesional skin area matched to selected AD participants, received no treatment, and were considered as a control group.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dupilumab (SAR231893)
2015
Completed Phase 4
~320

Find a Location

Who is running the clinical trial?

SanofiLead Sponsor
2,164 Previous Clinical Trials
3,514,926 Total Patients Enrolled
Regeneron PharmaceuticalsIndustry Sponsor
621 Previous Clinical Trials
380,551 Total Patients Enrolled
Clinical Sciences & OperationsStudy DirectorSanofi
862 Previous Clinical Trials
2,019,784 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
2021. "Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04823130.
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top